296 related articles for article (PubMed ID: 29393163)
1. Long-Term Imatinib Treatment for Patients with Unresectable or Recurrent Gastrointestinal Stromal Tumors.
Ogata K; Kimura A; Nakazawa N; Suzuki M; Yanoma T; Ubukata Y; Iwamatsu K; Kogure N; Yanai M; Kuwano H
Digestion; 2018; 97(1):20-25. PubMed ID: 29393163
[TBL] [Abstract][Full Text] [Related]
2. A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
Ogata K; Mochiki E; Ojima H; Haga N; Fukuchi M; Aihara R; Ando H; Uchida N; Toyomasu Y; Suzuki M; Kimura A; Kogure N; Yokobori T; Ohno T; Kuwano H
J Surg Oncol; 2014 Dec; 110(8):942-6. PubMed ID: 25164620
[TBL] [Abstract][Full Text] [Related]
3. Imatinib Mesylate for Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors: 10-Year Experience From Vietnam.
Hung KD; Van QL; Hoang GN; Bich PNT
Cancer Control; 2019; 26(1):1073274819863776. PubMed ID: 31319677
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
5. Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors: A single-center analysis.
Wang J; Yin Y; Shen C; Yin X; Cai Z; Pu L; Fu W; Wang Y; Zhang B
Medicine (Baltimore); 2020 Feb; 99(9):e19275. PubMed ID: 32118738
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
Kim JH; Ryu MH; Yoo C; Chae H; Na H; Beck M; Kim BS; Yoo MW; Yook JH; Kim BS; Kim KH; Kim CW; Kang YK
Cancer Med; 2019 Mar; 8(3):1034-1043. PubMed ID: 30693663
[TBL] [Abstract][Full Text] [Related]
7. Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.
Kanda T; Ishikawa T; Hirota S; Yajima K; Kosugi S; Ohashi M; Suzuki S; Mashima Y; Ajioka Y; Hatakeyama K
Jpn J Clin Oncol; 2012 Jul; 42(7):578-85. PubMed ID: 22523393
[TBL] [Abstract][Full Text] [Related]
8. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).
Rubió-Casadevall J; Martinez-Trufero J; Garcia-Albeniz X; Calabuig S; Lopez-Pousa A; Del Muro JG; Fra J; Redondo A; Lainez N; Poveda A; Valverde C; De Juan A; Sevilla I; Casado A; Andres R; Cruz J; Martin-Broto J; Maurel J;
Ann Surg Oncol; 2015 Sep; 22(9):2948-57. PubMed ID: 25608769
[TBL] [Abstract][Full Text] [Related]
9. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
Cavnar MJ; Wang L; Balachandran VP; Antonescu CR; Tap WD; Keohan M; Singer S; Temple L; Nash GM; Weiser MR; Guillem JG; Aguilar JG; DeMatteo RP; Paty PB
Ann Surg Oncol; 2017 Dec; 24(13):3972-3980. PubMed ID: 29058144
[TBL] [Abstract][Full Text] [Related]
10. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
Serrano C; García-Del-Muro X; Valverde C; Sebio A; Durán J; Manzano A; Pajares I; Hindi N; Landolfi S; Jiménez L; Rubió-Casadevall J; Estival A; Lavernia J; Safont MJ; Pericay C; Díaz-Beveridge R; Martínez-Marín V; Vicente-Baz D; Vivancos A; Hernández-Losa J; Arribas J; Carles J
Oncologist; 2019 May; 24(5):680-687. PubMed ID: 30126859
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
Fu Y; Hao H; Guo L; Yang G; Zhang X
Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study.
Hompland I; Boye K; Wiedswang AM; Papakonstantinou A; Røsok B; Joensuu H; Bruland Ø
Acta Oncol; 2024 May; 63():288-293. PubMed ID: 38712513
[TBL] [Abstract][Full Text] [Related]
15. The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.
Barrios CH; Blackstein ME; Blay JY; Casali PG; Chacon M; Gu J; Kang YK; Nishida T; Purkayastha D; Woodman RC; Reichardt P
Eur J Cancer; 2015 Nov; 51(16):2423-33. PubMed ID: 26248685
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological characteristics and their effect on survival in elderly patients with gastrointestinal stromal tumors.
Molinas Mandel N; Selcukbiricik F; Kanitez M; Yalcin S; Tural D; Erdamar S; Dogusoy G; Demir G
J BUON; 2016; 21(2):360-5. PubMed ID: 27273945
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China.
Shi YN; Li Y; Wang LP; Wang ZH; Liang XB; Liang H; Zhang L; Li B; Fan LQ; Zhao Q; Ma ZX; Zhao XF; Zhang ZD; Liu Y; Tan BB; Wang D; Wang LL; Hao YJ; Jia N
Medicine (Baltimore); 2017 Nov; 96(46):e8240. PubMed ID: 29145240
[TBL] [Abstract][Full Text] [Related]
18. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors after imatinib secondary resistance: survival analysis in patients with unresectable and metastatic gastrointestinal stromal tumors.
Kanda T; Ishikawa T; Kosugi SI; Ueki K; Naito T; Wakai T; Hirota S
Int J Clin Oncol; 2016 Apr; 21(2):295-301. PubMed ID: 26386705
[TBL] [Abstract][Full Text] [Related]
20. The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study.
Yang W; Liu Q; Lin G; Zhang B; Cao H; Zhao Y; Xia L; Feng F; Xiong Z; Hu J; Ye Y; Tao K; Zhang P
J Surg Oncol; 2021 Dec; 124(7):1128-1135. PubMed ID: 34324197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
